|Articles|February 21, 2013

New Class of Compounds is Capable of Killing Influenza Virus

Simon Fraser University virologist Masahiro Niikura and his doctoral student Nicole Bance are among an international group of scientists that has discovered a new class of molecular compounds capable of killing the influenza virus.

Working on the premise that too much of a good thing can be a killer, the scientists have advanced previous researchers methods of manipulating an enzyme that is key to how influenza replicates and spreads.

Their new compounds will lead to a new generation of anti-influenza drugs that the virus strains cant adapt to, and resist, as easily as they do Tamiful. Its an anti-influenza drug that is becoming less effective against the constantly mutating flu virus.

These increasingly less adequate anti-influenza drugs are currently doctors best weapons against influenza. They helped the world beat H1N1, swine flu, into submission four years ago.

The journal Science Express has just published online the scientists study, revealing how to use their newly discovered compounds to interrupt the enzyme neuraminidases facilitation of influenzas spread.

Tamiful and another anti-influenza drug, Relenza, focus on interrupting neuraminidases ability to help influenza detach from an infected cells surface by digesting sialic acid, a sugar on the surface of the cell. The flu virus uses the same sugar to stick to the cell while invading it. Once attached, influenza can invade the cell and replicate.

This is where the newly discovered compounds come to the still-healthy cells rescue. They clog up neuraminidase, stopping the enzyme from dissolving the sialic acid, which prevents the virus from escaping the infected cell and spreading.

The new compounds are also more effective because theyre water-soluble. They reach the patients throat where the flu virus is replicating after being taken orally, says Niikura, a Faculty of Health Sciences associate professor.

Influenza develops resistance to Replenza less frequently, but its not the drug of choice like Tamiful because its not water-soluble and has to be taken as a nasal spray.

Our new compounds are structurally more similar to sialic acid than Tamiful. We expect this closer match will make it much more difficult for influenza to adapt to new drugs.

Ultimately, the new compounds will buy scientists more time to develop new vaccines for emerging strains of influenza that are resistant to existing vaccines.

Source: Simon Fraser University


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERISS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.